Table 1.

Characteristics of trials included in review

				Tacrolimus			Ciclosporin			Co-interventions†
Trials*(stratified by formulation of ciclosporin comparator)					Concentration (ng/ml)			Concentration (ng/ml)
	No	Cadaveric donor (%)	First transplant (%)	Initial dose (mg/kg/d)	Initial	Three month	Initial dose (mg/kg/d)	Initial	Three month	Antiproliferative agent: Aza (mg/kg/d), MMF (g/d)	Other	Length of follow-up (years)
Solution (Sandimmun)
Ichimaru 200120	32	NS	NS	NS	10-15	10-15	NS	150-200	150-200	MMF (NS)	Mizoribine	0.5
Laskow 199522	130	100	100	0.2-0.4	5-40	5-40	6-14	NS	NS	Aza (1-1.5)	ALG	1
Mayer 199725	448	100	90	0.3	10-20	5-15	8	100-300	100-150	Aza (1-2)		5
Pirsch 199729	412	100	87	0.2	10-25	5-15	10	150-400	100-300	Aza (1.5)	ATG/OKT3	5
Radermacher 199830	48	NS	75	0.2-0.3	10-20	5-15	5-8	150	100-150	Aza (1.1)		1
Shapiro 199132	57	100	100	0.3	NS	NS	4 IV	NS	NS	NS		1
Microemulsion (Neoral)
Agha 200112‡	28	68	NS	NS	NS	NS	NS	NS	NS	Aza (NS)	ATG	0.2
Busque 200114	67	100	100	NS	8-16	5-15	NS	200-400	100-300	Aza (1.5-2), MMF (2)		0.5
Campos 200215	166	49	95	0.2	15-20	10-15	10	300-400	200-400	Aza (1.5-2)		1
Charpentier 200216	555	NS	NS	0.3	10-20	5-15	8	150-300	100-200	Aza (1-2)	ATG	0.5
Egfjord 200217‡	60	NS	NS	NS	NS	NS	NS	NS	NS	MMF (NS)	ATG	3.5
El Haggan 200218	44	100	NS	NS	NS	5-10	NS	NS	150-200	MMF (2)	ATG	1
Johnson 200021	223	100	100	0.15-0.2	8-16	5-15	8-10	200-400	100-300	Aza (1.5-2), MMF (2)	ATG/OKT3	3
Margreiter 200224	560	96	93	0.3	10-20	5-15	8-10	100-400	100-200	Aza (1-2)		3
Miller 200226	150	100	100	0.2	10	6-8	10	200-250	175-225	MMF (2) Sirolimus (8)	Daclizumab	1
Morris-Stiff 199827	179	100	83	0.2	5-15	5-15	8	100-200	100-200	Aza (1.5)		3
Nichelle 200228	94	NS	NS	0.2	5-10	5-10	6	100-150	100-150	Aza (1)		3
Raofi 199931	35	100	100	NS	10-15	10-15	NS	150-200	150-200	Cy:Aza (2) T: nil	OKT3	1
Toz 200133‡	17	65	NS	0.1-0.2	8-11	NS	5-7	250-320	NS	Aza (NS)		0.25
Trompeter 200234	204	16	88	0.3	10-20	5-10	150	150-200	100-200	Aza (2)		0.5
Tsinalis 200035‡	53	NS	NS	NS	NS	NS	NS	NS	NS	T:Aza (NS), Cy: MMF (NS)		0.5
Wang 200037	57	100	NS	0.15-0.3	10-20	5-10	6-8	250-400	150-300	MMF (2)		1
White 200039	102	79§	88	0.1-0.2	8-15	5-10	7-15	200-300	100-200	None		1
Yang 199940	60	62	100	0.16	15-20	10-20	8	300-400	200-300	MMF (1)	OKT3	1
Yu 200041	90	100	NS	0.15-0.3	10-20	10-20	8	NS	200-400	Aza (NS), MMF (1)		0.5
Unknown
Baskin 200213‡	81	Ns	NS	0.1-0.3	10-25	10-25	5-7	150-200	150-250	Aza (1.5), MMF (2)		0.5
Heering 199819	16	Ns	NS	10-20	10-20	5-10	10	100-300	100-150	Aza (2)		0.5
Liu 200323	27	100	NS	0.1-0.2	6-8	6-8	5-7	220-300	220-300	MMF (1.5-2)	ALG	0.5
Van Duijnhoven 200236	23	100	78	0.3	10-15	7-10	8	100-200	100-150	Aza (2)		0.5
Weimer 200238	84	75	<100	NS	NS	NS	NS	NS	NS	Aza (NS), MMF (NS)	ATG	0.25

IV=intravenous; NS=not stated.

^*Trials named by first author and year of first full publication. Data reported may be derived from this publication or from additional reports of the same trial

^†Prednisolone was common to all trials. T=tacrolimus; Cy=ciclosporin; Aza=azathioprine; MMF=mycophenolate; ATG=antithymocyte globulin; ALG=antilymphocyte globulin, OKT3=monomunab-CD3.

^‡Trials reported only in abstract form.

^§Includes 40% non-heart beating donors.